We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FTC is arguing that a district court erred in failing to apply the Supreme Court ruling in FTC v. Actavis in a pay-for-delay case involving GlaxoSmithKline’s Wellbutrin XL antidepressant. Read More
Amgen is taking Novartis’s biosimilar division to court over alleged patent infringement for seeking FDA approval to produce a biosimilar of its blockbuster therapy Enbrel. Read More
The FTC is suing Endo Pharmaceuticals and several other drugmakers over what it calls the illegal use of pay-for-delay settlements to block the market entry of generic forms of Opana ER and Lidoderm. Read More
An ex-Turing executive took his former employer to task in March, telling lawmakers the drugmaker’s decision to raise the price of Daraprim by 5,000 percent was “unjustified.” Read More
Although it has no drugs on the market, KaloBios Pharmaceuticals has announced that it will limit price increases to the rate of inflation or Consumer Price Index, and will do so no more than once a year. Read More
Two lawmakers are mulling contempt proceedings against outgoing Valeant CEO J. Michael Pearson after he failed to provide a deposition on Friday as part of an investigation into drug pricing. Read More
A federal judge has dismissed a major portion of the lawsuits accusing Pfizer of failing to warn about possible birth defects associated with taking the antidepressant Zoloft during pregnancy. Read More
Five companies are throwing their support behind Sequenom’s efforts to have the U.S. Supreme Court reconsider the limits of patent eligibility. Read More